"Cellestis is aiming for its speedier QuantiFERON-TB Gold test to capture at least 15 per cent of the US market (about 10 million tests a year) by 2008."
was extracted from an article in The Age written by Rebecca Urban in 2006. Ms Urban continues;
"The biotech sector occasionally cops flak for attracting spruikers, but Dr Radford and Dr Rothel are the exact opposite.
Cautious, bordering on reticent, they refuse to talk up sales figures or flood the market with boastful, but immaterial, announcements.
Asked when the company might break even, Dr Radford said he would prefer not to make promises."
CST Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held